EVOK vs. SEEL, ZVSA, SNGX, GTBP, RNAZ, THAR, PHAS, BCEL, LGVN, and GNPX
Should you be buying Evoke Pharma stock or one of its competitors? The main competitors of Evoke Pharma include Seelos Therapeutics (SEEL), ZyVersa Therapeutics (ZVSA), Soligenix (SNGX), GT Biopharma (GTBP), TransCode Therapeutics (RNAZ), Tharimmune (THAR), PhaseBio Pharmaceuticals (PHAS), Atreca (BCEL), Longeveron (LGVN), and Genprex (GNPX). These companies are all part of the "pharmaceutical preparations" industry.
Seelos Therapeutics (NASDAQ:SEEL) and Evoke Pharma (NASDAQ:EVOK) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, community ranking, risk and earnings.
Seelos Therapeutics has a beta of 2.03, suggesting that its share price is 103% more volatile than the S&P 500. Comparatively, Evoke Pharma has a beta of 0.38, suggesting that its share price is 62% less volatile than the S&P 500.
In the previous week, Seelos Therapeutics and Seelos Therapeutics both had 2 articles in the media. Seelos Therapeutics' average media sentiment score of 0.33 beat Evoke Pharma's score of -0.27 indicating that Evoke Pharma is being referred to more favorably in the news media.
Evoke Pharma has higher revenue and earnings than Seelos Therapeutics.
Seelos Therapeutics presently has a consensus target price of $70.00, indicating a potential upside of 23,701.43%. Given Evoke Pharma's higher possible upside, equities analysts clearly believe Seelos Therapeutics is more favorable than Evoke Pharma.
Evoke Pharma has a net margin of -150.43% compared to Evoke Pharma's net margin of -1,719.56%. Evoke Pharma's return on equity of 0.00% beat Seelos Therapeutics' return on equity.
Evoke Pharma received 289 more outperform votes than Seelos Therapeutics when rated by MarketBeat users. However, 66.36% of users gave Seelos Therapeutics an outperform vote while only 62.50% of users gave Evoke Pharma an outperform vote.
23.4% of Seelos Therapeutics shares are held by institutional investors. 5.4% of Seelos Therapeutics shares are held by company insiders. Comparatively, 6.1% of Evoke Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Seelos Therapeutics and Evoke Pharma tied by winning 7 of the 14 factors compared between the two stocks.
Get Evoke Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for EVOK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EVOK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Evoke Pharma Competitors List
Related Companies and Tools
